Livzon Pharmaceutical Group (HK:1513) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Livzon Pharmaceutical Group’s subsidiary, Shanghai Livzon Pharmaceutical Manufacturing, has achieved a significant milestone as its Leuprorelin Acetate Microspheres for Injection successfully passed quality and efficacy consistency evaluation by the National Medical Products Administration. This approval enhances the company’s position in the generic drug market, potentially boosting investor confidence. Such developments could positively impact Livzon Pharmaceutical’s stock performance.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.